Wealthspire Advisors LLC Sells 805 Shares of Zoetis Inc. (NYSE:ZTS)

Wealthspire Advisors LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 11.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,265 shares of the company’s stock after selling 805 shares during the quarter. Wealthspire Advisors LLC’s holdings in Zoetis were worth $1,021,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. AMF Tjanstepension AB raised its holdings in Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after buying an additional 20,001 shares during the last quarter. Howard Capital Management Group LLC raised its holdings in Zoetis by 0.8% in the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after acquiring an additional 883 shares during the last quarter. Arkadios Wealth Advisors boosted its stake in Zoetis by 2.5% during the 3rd quarter. Arkadios Wealth Advisors now owns 5,045 shares of the company’s stock valued at $986,000 after purchasing an additional 121 shares during the last quarter. Pallas Capital Advisors LLC increased its holdings in shares of Zoetis by 6.0% in the 3rd quarter. Pallas Capital Advisors LLC now owns 7,934 shares of the company’s stock worth $1,440,000 after purchasing an additional 451 shares in the last quarter. Finally, SFE Investment Counsel raised its stake in shares of Zoetis by 1.9% in the third quarter. SFE Investment Counsel now owns 27,461 shares of the company’s stock worth $5,365,000 after purchasing an additional 514 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ZTS shares. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Stifel Nicolaus lowered their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Piper Sandler dropped their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Buy” and an average price target of $215.40.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Zoetis Trading Up 2.0 %

Shares of Zoetis stock opened at $168.60 on Wednesday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm’s 50 day simple moving average is $166.26 and its two-hundred day simple moving average is $177.66. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The firm has a market capitalization of $75.50 billion, a price-to-earnings ratio of 30.82, a PEG ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.19%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.